Biopharma funding rebounds in 2026, but capital flows to lower-risk assets
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Subscribe To Our Newsletter & Stay Updated